ABSTRACT:
Mycobacterium tuberculosis is a significant source of global morbidity and mortality. Moxifloxacin and other fluoroquinolones are important therapeutics for the treatment of tuberculosis, particularly multi-drug resistant infections. In order to guide the development of new quinolone-based agents, it is critical to understand the basis of drug action against M. tuberculosis gyrase and how mutations in the enzyme cause resistance. Therefore, we characterized interactions of fluoroquinolones and related drugs with wild-type gyrase and enzymes carrying mutations at GyrA A90 and GyrA D94 . M.
tuberculosis gyrase lacks a conserved serine that anchors a water-metal ion bridge that is critical for quinolone interactions with other bacterial type II topoisomerases. Despite the fact that the serine is replaced by an alanine (GyrA A90 ) in M. tuberculosis gyrase, the bridge still forms and plays a functional role in mediating quinolone-gyrase interactions. Clinically relevant mutations at GyrA A90 and GyrA D94 cause quinolone resistance by disrupting the bridge-enzyme interaction, thereby decreasing drug affinity. Fluoroquinolone activity against wild-type and resistant enzymes can be enhanced by the introduction of specific groups at the C7 and C8 positions. By dissecting fluoroquinolone-enzyme interactions, we determined that an 8-methyl-moxifloxacin derivative induces high levels of stable cleavage complexes with wild-type gyrase and two common resistant enzymes, GyrA A90V and GyrA
D94G
. 8-Methyl-moxifloxacin was ~2 times more potent than moxifloxacin against wild-type M. tuberculosis gyrase and displayed higher activity against the mutant enzymes than moxifloxacin did against wild-type gyrase. This chemical biology approach to defining drug-enzyme interactions has the potential to identify novel drugs with improved activity against tuberculosis.
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SIGNIFICANCE STATEMENT:
Moxifloxacin and other fluoroquinolone antibacterials are important anti-tuberculosis therapeutics.
Fluoroquinolones kill Mycobacterium tuberculosis, the causative agent of tuberculosis, by increasing levels of DNA breaks generated by gyrase, an essential type II topoisomerase that regulates DNA topology. As fluoroquinolone usage in anti-tuberculosis regimens is becoming more pronounced, understanding the basis of drug-gyrase interactions and resistance is becoming more important. Using a mechanism-based chemical biology approach, our work identified critical drug features that mediate fluoroquinolone interactions with M. tuberculosis gyrase and determined the biochemical basis for fluoroquinolone resistance caused by the most common clinical mutations in gyrase. These findings allowed us to identify a moxifloxacin derivative that displays enhanced activity against wild-type gyrase and maintains high activity against clinically relevant resistant enzymes.
\body Tuberculosis is a major cause of morbidity and mortality on a global scale and is second only to HIV/AIDS as the most prolific killer due to a single infectious agent (1). According to the World Health Organization, 9 million people were diagnosed with tuberculosis in 2013, and 1.5 million died from the disease (1). The standard treatment regimen for tuberculosis is a 6-month course that includes a combination of rifampin, isoniazid, pyrazinamide, and ethambutol (2, 3). However, fluoroquinolones are becoming more important in the treatment of tuberculosis and are routinely used in multi-drug resistant cases and in patients who are intolerant of first-line therapy (2, 4, 5) .
Furthermore, moxifloxacin (a newer generation fluoroquinolone) has shown promising results as a potential first-line agent as part of the PaMZ regimen (PA-824, moxifloxacin, and pyrazinamide), which currently is in clinical trials (6).
Fluoroquinolones are broad-spectrum antibacterials that act by increasing levels of DNA strand breaks generated by type II topoisomerases (7) (8) (9) (10) (11) (12) . Most bacterial species encode two type II enzymes, gyrase and topoisomerase IV (8, 10, (12) (13) (14) . In these species, gyrase regulates the superhelical density of the bacterial chromosome and removes torsional stress that is generated ahead of DNA replication forks and transcription complexes, and topoisomerase IV primarily unknots and untangles DNA (11, 15, 16) . Mycobacterium tuberculosis, the causative agent of tuberculosis, is unusual in that it encodes only gyrase (17) . As a result, this enzyme displays functional properties of both type II topoisomerases (18) .
Recent structural (19) and functional (20, 21) studies with topoisomerase IV indicate that quinolones interact with bacterial type II enzymes primarily through a water-metal ion bridge. This bridge is formed by a divalent metal ion that is chelated by the C3/C4 keto acid of the drug and stabilized by four water molecules (19) . Two of these water molecules are coordinated by a conserved serine and acidic residue (located four positions downstream) in the A subunit of the enzyme. Substitutions in the residues that anchor the bridge are the most prevalent cause of quinolone resistance (10) (11) (12) (13) (22) (23) (24) (25) (26) (27) . In most species, the serine is mutated far more often than the acidic residue.
In contrast to most bacterial species, M. tuberculosis gyrase contains an alanine (A90) in place of the conserved serine. This situation raises the issue of whether the water-metal ion bridge can be formed or plays a role in mediating quinolone activity in this species. However, the fact that mutations at A90 and the acidic residue (D94) are associated with clinical quinolone resistance in M. tuberculosis (28) suggests that the bridge contributes to quinolone function.
Fluoroquinolones are commonly prescribed for community-acquired pneumonia that is later diagnosed as pulmonary tuberculosis (29) . This prior treatment is associated with an increased incidence of fluoroquinolone-resistant disease (30, 31) . As the use of fluoroquinolones in treating tuberculosis is becoming more pronounced, understanding the basis of drug-gyrase interactions and resistance is becoming more important. Therefore, we analyzed the interactions of fluoroquinolones and related compounds with wild-type and resistant mutant M. tuberculosis gyrase. Results indicate that the water-metal ion bridge is partially functional in wild-type gyrase and that the most common resistance mutations cause a decrease in bridge-mediated drug affinity for the enzyme. In contrast to other species (32, 33) , quinolone interactions within the gyrase-cleaved DNA complex depend more heavily on substituents at C7 and C8. Based on an analysis of structure-activity relationships at these two positions, we identified fluoroquinolones that display significantly improved activity against wild-type and resistant M. tuberculosis gyrase as compared to moxifloxacin.
Results and Discussion
Gyrase is a heterotetramer comprised of two subunits, GyrA (which contains the active site tyrosine that cleaves and ligates DNA) and GyrB (which contains the ATPase and metal-binding domains) (8, 10, (12) (13) (14) . To characterize interactions between quinolones and M. tuberculosis gyrase, we utilized wild-type enzyme and GyrA
A90S
, GyrA
A90V
D94G
, and GyrA
D94H
. Amino acid residues A90 and D94 occur at the positions that, by sequence homology, are predicted to anchor the watermetal ion bridge if it is used to mediate quinolone-enzyme interactions in this species (19) (20) (21) , and GyrA D94H mutant proteins. As shown previously, the D94G and D94H
mutations caused a higher level of fluoroquinolone resistance than the A90V mutation (36, 37).
The above findings are consistent with the hypothesis that fluoroquinolones interact with wildtype M. tuberculosis gyrase through a water-metal ion bridge that is anchored primarily by D94. To investigate this possibility, the activity of ciprofloxacin and moxifloxacin against GyrA A90S was examined. The inclusion of the serine residue in place of the alanine provides the potential to reconstitute a fully functional bridge. As seen in Figure 2 (top), both fluoroquinolones displayed dramatically higher activity against GyrA A90S than they did against wild-type gyrase: drug potency 6 (i.e., drug concentration required to induce 50% maximal DNA cleavage) was ~5-fold higher and levels of cleavage at 100 µM were ~2-fold higher. Collectively, these findings suggest that there is sufficient conservation of structure such that M. tuberculosis gyrase is capable of using a watermetal ion bridge to mediate fluoroquinolone-enzyme interactions. This conclusion is supported by the structural studies in the accompanying paper by Blower et al. (34) .
Quinazolinediones are fluoroquinolone-like compounds that lack the C3/C4 keto acid required to chelate metal ions. In several other species, quinazolinediones containing a 3'- Fluoroquinolones that have a C8 substituent generally display better activity against clinical tuberculosis isolates than do derivatives with a C8-H (43, 44). Therefore, 3'-(AM)Pquinazolinedione and -fluoroquinolone derivatives that contained a C8-H were used to examine the influence of the C8 substituent on drug activity (Figure 2 , bottom). The activity of 8-H-3'-(AM)Pdione was markedly decreased against all of the enzymes, confirming that the C8 methyl group plays an important role in mediating the activity of these compounds. The activity of 8-H-3'-(AM)P-FQ also decreased with each enzyme as compared to the C8-methyl version of this fluoroquinolone. The relative activity of 8-H-3'-(AM)P-FQ correlated with the capacity of each enzyme to anchor the water-metal ion bridge.
Taken together, the above findings strongly suggest that wild-type M. tuberculosis gyrase partially supports the water-metal ion bridge and that the bridge and the C7 and C8 substituents play important roles in supporting quinolone activity. Therefore, the contributions of these three drug features to quinolone interactions and activity were analyzed in greater detail.
Role of the Water-Metal Ion Bridge in Facilitating Quinolone Activity Against M. tuberculosis
Gyrase. To determine whether quinolone interactions with M. tuberculosis gyrase are mediated by the water-metal ion bridge, Mg 2+ titrations were carried out to assess the effects of A90 mutations on the metal ion concentration required to support DNA cleavage induced by ciprofloxacin ( Figure   3 , left). The amino acid at this position plays a critical role in anchoring the water-metal ion bridge in other bacterial type II enzymes (20, 21, 33) . Results with wild-type gyrase were compared to those of mutant enzymes containing a serine or a valine in place of the alanine at position 90. The GyrA A90S mutant enzyme, which contains the conserved serine residue found in most other bacterial type II enzymes and greatly enhances fluoroquinolone activity (see Figure 2) , required a lower concentration of Mg 2+ to achieve half-maximal and maximal levels of quinolone-induced DNA cleavage. In marked contrast, the GyrA A90V mutant enzyme, which causes quinolone resistance (see Figure 2 ), required a higher concentration of Mg 2+ to achieve half-maximal and maximal levels of quinolone-induced DNA cleavage.
These results demonstrate that the amino acid at position 90 affects the affinity of the divalent metal ion that is chelated by the quinolone and indicate that the water-metal ion bridge is a point of contact between quinolones and M. tuberculosis gyrase. It is likely that the alanine at position 90 in wild-type gyrase, while not serving as a bridge anchor, still allows D94 to anchor the bridge.
However, because M. tuberculosis gyrase has only one available amino acid to anchor the bridge, fluoroquinolone interactions are weaker than seen with species that encode two amino acid bridge anchors (20, 21, 33) . Substitution of A90 with the larger valine may cause quinolone resistance by interfering with the ability of water molecules to coordinate properly with the Mg 2+ or by impeding D94 interactions with the bridge.
As a control for the above experiment, the effects of A90 mutations on the Mg 2+ requirement for DNA cleavage induced by 8-methyl-3'-(AM)P-dione (which does not require a metal ion for enzyme interactions) were determined. In contrast to results with ciprofloxacin, similar levels of Mg 2+ were required to achieve half-maximal and maximal cleavage with all three enzymes ( Figure   3 , right).
In other bacterial type II topoisomerases, mutations in bridge-anchoring residues that partially disrupt the water-metal ion bridge often restrict the variety of metal ions that can be used to form the bridge (21, 33) . Therefore, we examined the ability of a second divalent metal ion, Mn , which has a fully intact bridge, the level of ciprofloxacin-induced DNA cleavage was unaffected by the substitution of this metal ion for Mg 2+ . However, with wild-type gyrase, which has a partially disrupted bridge, ciprofloxacin activity was decreased ~2-fold.
Furthermore, with GyrA
A90V
, which has a more severely disrupted bridge, the quinolone displayed no ability to enhance enzyme-mediated DNA cleavage in the presence of Mn
2+
. Therefore, relative levels of resistance seen with enzymes containing mutations in bridge-anchoring residues can be altered by the metal ion used to support this interaction. A stronger water-metal ion bridge allows more latitude with metal ion requirements.
The water-metal ion bridge has been shown to play critical roles in mediating fluoroquinolone binding and positioning, but its predominant role appears to differ across species. With B. anthracis topoisomerase IV, it primarily acts as a binding contact (20, 21) . However, with E. coli topoisomerase IV, it has little effect on drug affinity and is believed to properly position the drug in a manner that promotes DNA cleavage (33) . Therefore, to determine whether the water-metal ion bridge plays a major role in drug-enzyme binding in M. tuberculosis gyrase, we used a competition approach and examined the effects of ciprofloxacin on DNA cleavage induced by 10 µM 8-methyl- Therefore, we compared the activities of fluoroquinolones containing a C8-H, -methyl, or -methoxy group against the wild-type and resistant enzymes. Two parallel series were examined: one that contained the C7 piperazinyl ring of ciprofloxacin, and one that contained the C7 diazabicyclononyl ring of moxifloxacin.
The first set of experiments examined drug effects against wild-type gyrase. In general, the inclusion of a C8 substituent enhanced quinolone activity ( Figure 6 , top left). For the ciprofloxacinbased series, the compound with a C8 methoxy group generated the highest level of DNA cleavage activity. Compared to ciprofloxacin, 8-methoxy-cipro induced ~50% more cleavage at 100 µM drug and displayed a potency that was ~2-fold higher (based on the drug concentration required to induce 50% of the cleavage generated at 100 µM drug). The presence of a C8 methyl group enhanced DNA cleavage, but to a lesser extent than did the methoxy group.
A more dramatic effect was seen when the C8 methoxy group of moxifloxacin was replaced with a methyl group. Compared to moxifloxacin (the fluoroquinolone most commonly used to treat tuberculosis) (2, 4-6), 8-methyl-moxi induced ~2-fold more cleavage at 100 µM drug and was ~2-fold more potent. Furthermore, only 10 µM 8-methyl-moxi was required to induce the same level of scission (~30%) as was seen with 100 µM moxifloxacin. In contrast, 8-H-moxi displayed an activity similar to that of moxifloxacin.
The second set of experiments examined the effects of the C8 substituent on fluoroquinolone activity against the resistant GyrA A90V and GyrA D94G mutant enzymes ( Figure 6 , top right and bottom left, respectively). When the function of the water-metal ion bridge was disrupted, the C8 substituent had a much greater influence on drug activity. Drugs lacking a C8 substituent (ciprofloxacin and 8-H-moxi) showed little activity against either fluoroquinolone-resistant enzyme.
However, in the presence of either a C8 methyl or methoxy substituent, high levels of activity were maintained. To this point, 8-methyl-moxi displayed nearly wild-type activity against GyrA Cells were sonicated and centrifuged, and the clarified lysate was passed over a HisTrap HP column (GE Healthcare). His-tagged protein was eluted with buffer B [20 mM Tris-HCl (pH 7.9), 500 mM NaCl, 250 mM imidazole, and 10% glycerol with protease inhibitors], then concentrated and exchanged into buffer A overnight at 4 °C, in the presence of His-tagged TEV protease. This mixture was passed over a HisTrap HP column, and the flow-through was collected, concentrated,
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and run over an S-300 gel filtration column (GE Healthcare) in buffer C [50 mM Tris-HCl (pH 7.9), 500 mM KCl, 2 mM β-mercaptoethanol, and 10% glycerol]. Peak fractions were pooled, concentrated, and diluted into a high-glycerol variant of buffer C, so that the final glycerol concentration reached 30% prior to storage at -80 °C.
Human topoisomerase IIα was expressed in yeast and purified as described by Kingma et al.
(48).
Negatively supercoiled pBR322 plasmid DNA was prepared from E. coli using a Plasmid
Mega Kit (Qiagen) as described by the manufacturer. Relaxed pBR322 plasmid DNA was generated by treatment with topoisomerase I for 30 min as previously described (49), followed by phenol-chloroform-isoamyl alcohol extraction, ethanol precipitation, and resuspension in 5 mM
Tris-HCl (pH 8.5) and 500 µM EDTA. MgCl2, 100 mM KCl, 100 µM EDTA, 25 µM dithiothreitol, and 2.5% (v/v) glycerol. All reaction mixtures were incubated at 37 °C for 10 min, and enzyme-DNA cleavage complexes were trapped by the addition of 2 µL of 5% SDS followed by 2 µL of 250 mM EDTA (pH 8.0). Proteinase K (2 µL of a 0.8 mg/mL solution) was added, and samples were incubated at 45 °C for 45 min to digest the enzyme. Samples were mixed with 2 µL of agarose gel loading buffer, heated at 45 °C for 5 min, and subjected to electrophoresis in 1% agarose gels in 40 mM Tris-acetate (pH 8.3) and 2 mM EDTA containing 0.5 µg/mL ethidium bromide. DNA bands were visualized as described above.
DNA cleavage was monitored by the conversion of supercoiled plasmid to linear molecules.
Assays that monitored gyrase-mediated DNA cleavage in the absence of drugs substituted 6 mM CaCl2 for 6 mM MgCl2 in the reaction buffer. Assays that assessed DNA cleavage in the presence of drugs contained 0-100 µM compound. In some reactions, the concentration dependence of MgCl2 was examined or the divalent metal ion was replaced with 2.5 mM MnCl2.
For assays that monitored competition between two drugs, the compounds were added simultaneously to reaction mixtures, and the final concentrations of the compounds are indicated. In these competition assays, the level of cleavage seen with the corresponding concentration of the competing drug (in the absence of the drug held at a constant concentration) was used as a baseline and was subtracted from the cleavage level seen in the presence of both compounds.
Persistence of Gyrase-DNA Cleavage Complexes. The persistence of gyrase-DNA cleavage complexes established in the presence of drugs was determined using the procedure of Gentry et al.
as adapted by Aldred et al. (20, 51) . Initial reaction mixtures contained 500 nM wild-type or mutant gyrase, 50 nM DNA, and 100 µM ciprofloxacin, 50 µM 8-methoxy-cipro, 50 µM moxifloxacin, or 10 µM 8-methyl-moxi in a total of 20 µL of reaction buffer. Quinolone concentrations that yielded similar levels of DNA cleavage were used. Reaction mixtures were incubated at 37 ºC for 10 min and then diluted 20-fold with reaction buffer warmed to 37 ºC. Samples (20 µL) were removed at times ranging from 0-60 min for the mutant enzymes or 0-180 min for the wild-type enzyme, and DNA cleavage was stopped with 2 µL of 5% SDS followed by 2 µL of 250 mM EDTA (pH 8.0).
Samples were digested with proteinase K and processed as described above for DNA cleavage assays. Levels of DNA cleavage were set to 100% at time zero, and the persistence of cleavage complexes was determined by the loss of the linear reaction product over time. 
